Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

470.65 -0.47 (-0.10%)
Streaming Delayed Price Updated: 3:41 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
Is CRISPR Therapeutics Stock a Buy Now?
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
2 Unstoppable Growth Stocks That Could Turn $20,000 into $100,000 by 2030
These one-of-a-kind businesses have an edge over the competition that could steadily push their stock prices in the right direction through the end of the decade and beyond. 
Via The Motley Fool
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
$1000 Invested In This Stock 15 Years Ago Would Be Worth $10,000 Today
Via Benzinga
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
2 Market-Beating Stocks With Major Catalysts on the Way
Can these companies keep climbing? 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
All three of these stocks should be huge winners over the long run. 
Via The Motley Fool
2 Magnificent Growth Stocks to Buy Before the Next Bull Market
A bull market could be the tip of the iceberg for these businesses. 
Via The Motley Fool
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in June
There are always buying opportunities in the stock market. 
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than Later
These stocks are already performing well but could kick into higher gear in a new S&P 500 bull market. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?
This company might be worth a premium. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
All three trounced the market over the past 10 years. 
Via The Motley Fool
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
These businesses have considerable growth runways ahead. 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.